Cadila secures US FDA approval for epilepsy drug
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Cadila Healthcare Ltd., under the aegis of Zydus Cadila, secured the U.S. Food and Drug Administration approval for Felbamate tablets.
The drug is used for the treatment of seizures in people with epilepsy.
